Expanded Access to Burosumab
- Conditions
- X-linked HypophosphatemiaTumor-Induced Osteomalacia
- Registration Number
- NCT03775187
- Lead Sponsor
- Kyowa Kirin Co., Ltd.
- Brief Summary
Individual patient expanded access requests may be considered for patients who have no other treatment options
- Detailed Description
Expanded access may be available outside of the US in countries prior to approval by the local regulatory agencies. For full details, please visit the links provided below.
Recruitment & Eligibility
- Status
- AVAILABLE
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Exclusion Criteria
Study & Design
- Study Type
- EXPANDED_ACCESS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of burosumab in treating X-linked Hypophosphatemia and Tumor-Induced Osteomalacia?
How does burosumab compare to standard-of-care treatments for phosphate metabolism disorders in clinical efficacy?
Which biomarkers are used to select patients for expanded access burosumab therapy in phosphate-wasting conditions?
What adverse events are associated with long-term burosumab use in hypophosphatemia patients and how are they managed?
Are there combination therapies or alternative FGF23 inhibitors being developed by Kyowa Kirin for phosphate regulation disorders?